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Accepted 11 September 2015; Published online xxxxAbstractObjectives: To establish whether evidence about the effectiveness of a health care intervention is sufficient to justify the use of the
intervention in practice and show how value of information (VOI) analysis can be used to place a value on the need for additional evidence
and inform research prioritization decisions.
Study Design and Setting: Meta-analysis provides an estimate of the effect of an intervention with uncertainty. VOI analysis deter-
mines the adverse health consequences of not resolving this uncertainty. A case study examining the evidence before the high profile trial
of Corticosteroid Randomisation After Significant Head injury (CRASH) shows the consequences on patient outcomes if this trial had not
been successfully funded.
Results: The consequences of uncertainty before CRASH were high at 40 deaths and 1,067 years of full health per annum. VOI analysis
indicates that CRASH was worthwhile and the UK National Health Service would have had to spend an additional £205 million elsewhere
to generate health benefits similar to CRASH.
Conclusions: VOI analysis can be integrated with the results of meta-analysis to help inform whether a particular research proposal is
potentially worthwhile and whether it should be prioritized over other research topics that could be commissioned with the same re-
sources.  2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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The evidence about the effectiveness of a health care
intervention might suggest that it achieves better health
outcomes than the available alternative interventions.
However, the estimate of treatment effect may still be
uncertain, which creates uncertainty in any decision about
whether to use the intervention in clinical practice. If the
expected health benefits of the intervention are not realized
in practice, there may be a detrimental effect to patient
health outcomes. In addition, the resources committed byConflict of interest: None.
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licenses/by-nc-nd/4.0/).the use of the intervention may be wasted. Similarly, if
an intervention is not expected to perform better than the
available alternatives, rejecting its use in clinical practice
may risk failing to provide access to a valuable intervention
if the health benefits are actually greater than expected.
These uncertainties can never be entirely eliminated, but
they can be reduced by collecting further evidence, which
in turn facilitates better decisions for patient outcomes
and better use of finite resources.
Value of information (VOI) analysis provides a very use-
ful tool for establishing: (1) whether the evidence currently
available is sufficient to support the use of the intervention
in practice; (2) whether additional evidence is required to
resolve the uncertainties; (3) the type of evidence that is
required; and (4) the circumstances under which an inter-
vention should be withheld until additional evidence
becomes available [1e8]. There are now many applications
of VOI analysis in the context of decision models used to
estimate the cost effectiveness of alternative interventions.
In this article, we show that the same type of analysis caness article under the CC BY-NC-ND license (http://creativecommons.org/
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Key findings
 A simple extension of standard meta-analysis with
methods of value of information (VOI) analysis
provides an estimate of the health benefits of
further research, which can be used to inform
research prioritization and commissioning
decisions.
What this adds to what was known?
 Until now, methods of VOI analysis have been
applied to situations where probabilistic decision
analytic models or estimates of cost effectiveness
are available, but we show that the same principles
and methods are relevant to a range of different
types of health care systems and decision-making
contexts, even those where there is no explicit
assessment of cost effectiveness.
What is the implication and what should change
now?
 Research proposals that are likely to be worthwhile
can be identified in a systematic way. The health
benefits expected from different proposals,
competing for the same resources, can be
compared to each other to establish which topic of-
fers the greatest value. This adds transparency and
accountability to research prioritization decisions.
also be applied to standard results of meta-analysis, without
the necessity to undertake a cost-effectiveness analysis.
Furthermore, the methods provide a framework to assess
the relative importance of alternative research topics and
proposals, which is invaluable for research prioritization
decisions.
Meta-analysis provides an estimate of the magnitude of
treatment effect and the level of uncertainty in this esti-
mate, for example, the confidence interval (CI) around
the mean estimate of effect is used to represent the range
of values in which the unknown ‘‘true’’ effect lies [9].
When this uncertainty is combined with information about
baseline risk and incidence, the absolute effect of the uncer-
tainty on health outcomes can be assessed [10]. VOI anal-
ysis determines an estimate of the health benefits that could
be gained if the uncertainty about treatment choice was
resolved completely. These health benefits can then be
compared with the costs of undertaking the research to
establish whether it represents an efficient use of resources.
Furthermore, the health benefits of different research topics
(or proposals for funding) can be compared to establish
which topic should be prioritized from those competing
for the same resources.
2 C. McKenna et al. / Journal ofThis article shows how the methods of VOI analysis can
be integrated with the results of meta-analysis to directly
inform the questions posed in research prioritization and
commissioning decisions. We take as a starting point that
research proposals will include a systematic review of
existing evidence and, where appropriate, a meta-analysis
because funding additional research without knowledge of
existing evidence would seem inappropriate and potentially
unethical. We use the case of corticosteroids after traumatic
brain injury (TBI) to offer a demonstration of the ease with
which the methods can be applied.2. Corticosteroids after TBI
Despite 19 randomized controlled trials before the
CRASH trial (Corticosteroid Randomisation After Signifi-
cant Head injury) [11,12], the effect of corticosteroids on
death and disability after TBI remained unclear. The
CRASH trial was stopped early after enrolling 10,008
adults with TBI. It reported a higher risk of death or se-
vere disability associated with the use of corticosteroids
compared with not using them [12]. As a consequence
of this definitive, and to some extent, unexpected result
clinical practice changed dramatically, resulting in many
thousands of deaths averted around the world (before
CRASH, corticosteroids was used in 64% of patients with
TBI in the United States [13] and 12% in the United
Kingdom [14]). The global value of the CRASH trial ap-
pears, with hindsight, self-evident. However, the preven-
tion of thousands of unnecessary iatrogenic deaths
hinges on the fact that the funding application for CRASH
was successful. In this article, we conduct a retrospective
analysis of the evidence available before CRASH to show
how methods of VOI analysis would have been useful for
quantifying the value of obtaining further evidence and the
expected health consequences of not obtaining the
evidence.2.1. Evidence available before CRASH
The evidence from the trials comparing the use of corti-
costeroids to placebo or no treatment in acute TBI before
CRASH is illustrated in Fig. 1 for the primary end point
of mortality. These trials dating from 1972 to 1995 were
of varying study quality, length of follow-up, steroids
administered, doses, and time to administration [15e30].
Standard meta-analysis suggests substantial uncertainty
about the effectiveness of corticosteroids in TBI [31,32].
For example, a random-effects meta-analysis suggests that
the use of steroids after TBI reduces the risk of death with
an expected odds ratio (OR) of 0.93. However, the 95% CI
crosses the line of no difference indicating that the change
in the risk of death could be as much as 12.5% lower to
9.9% higher (using the average pooled death rate in the
control arms of 35.3%).
Fig. 1. Fixed and random-effects meta-analysis of the effect of corticosteroids on mortality. OR, odds ratio; CI, confidence interval.
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Uncertainty in the effect of corticosteroids on mortality
means that there is a chance that any decision about their
use in TBI will be incorrect. The impact of this uncertainty
on number of deaths per annum is obtained by sampling
from the uncertain distributions of relative effect and base-
line risk (estimated in the meta-analysis) and multiplying
by the annual incidence of TBI. For example, if we sampled
a relative effect of 0.90 and a baseline risk of 0.35 from the
uncertain distributions for treatment effect and baseline risk
of mortality, respectively, the number of deaths per annum
for an incidence of 1,000 is 315 (50.90  0.35  1000) in
the intervention group compared with 350 (50.35  1000)
in the control. In this case, the best treatment choice is the
intervention as it results in 35 fewer deaths per annum. This
process of sampling from the uncertain distributions is
repeated many times (e.g., 5,000 times) to derive a distribu-
tion of the consequences of uncertainty in number of deaths
per annum.
The resulting distribution of the number of deaths per
annum based on the evidence before CRASH is illustrated
in Fig. 2 for an annual incidence of 8,800 in United
Kingdom. If the use of corticosteroids before CRASH
had been based on the random-effect analysis which
favored their use (OR! 1.0), then there was a 74% chance
that corticosteroids were effective and improved survival.
However, there was a 26% chance that using corticosteroids
in TBI would result in excess deaths. Fig. 2 shows that
there was a greater likelihood of small numbers of excess
deaths (e.g., 19% chance of greater than 0 and 200 deathsper year) and a smaller likelihood of larger numbers of
excess deaths (e.g., 7% chance of O200 deaths per year).
The average over the distribution in Fig. 2 is the expected
(average) number of deaths per annum (40 deaths) due to
the uncertainty in the use of corticosteroids after TBI. This
value represents the maximum expected health benefits that
could be gained if the uncertainty about the effectiveness of
corticosteroids was resolved completely, that is, it repre-
sents an upper bound on the value of additional evidence
to resolve this uncertainty.
Before CRASH, clinical practice in the United Kingdom
did not reflect this balance of evidence that favored the use
of corticosteroids, partly due to the substantial uncertainty
about its effectiveness. Before CRASH, approximately
12% of patients with TBI received corticosteroids [14].
Therefore, the value of both implementing the uncertain
findings of existing research and acquiring additional evi-
dence is greater at 180 deaths per annum.4. Value of additional evidence about survival and
disability
Mortality is only one aspect of outcome in TBI because
the impact on disability and subsequent survival is also
important. Although the primary outcome reported in 16
of the trials was number of deaths [15e30], the Glasgow
Outcome Scale (GOS) [33], which categorizes people into
one of five health states: (1) dead; (2) persistent vegetative;
(3) severe disability; (4) moderate disability; and (5) recov-
ery, was also used to assess neurological outcomes in seven
Fig. 2. Distribution of the consequences of uncertainty in number of deaths per annum based on a random-effects meta-analysis of the effect of
corticosteroids on mortality after traumatic brain injury (TBI). There is a 74% chance that corticosteroids are effective and improve survival (i.e., a
probability of 0.74 of no deaths). However, because of the uncertainty in the effect of corticosteroids on mortality, there is a 26% chance that
corticosteroids will result in excess deaths compared with not using corticosteroids after TBI (control group). The number of excess deaths (x-axis)
is shown by the likelihood of them occurring (y-axis). For example, the second bar corresponding to [1,50] with a probability of 0.07 represents a
7% chance that the number of excess deaths from corticosteroid use is between 1 and 50 deaths per annum.
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combined number of people dead, vegetative, and severely
disabled at the end of study [24,25]. The meta-analysis can
therefore be extended to include the effects of corticoste-
roids on both survival and disability. Table 1 shows the pro-
portion of individuals expected to be in each of the GOS
outcomes based on a random-effects analysis of all out-
comes. The risk of being left in a vegetative or severely
disabled state was higher with the use of corticosteroids
compared with control, whereas the risk of being left
moderately disabled or making good recovery was lower
with corticosteroids.
When these important aspects of outcome are consid-
ered, the judgment about the effectiveness of corticoste-
roids and the uncertainty is changed. For example, when
the evidence for the worse health outcomes of death, vege-
tative, and severely disabled were combined, the OR was
1.10 (95% CI: 0.81, 1.53) against the use of corticosteroids.
By exploiting other external evidence, the outcome of sur-
vivors can be quantified in terms of their subsequent quality
of life. Shavelle et al. [35] estimated the expected life
expectancy of an individual after TBI by age and severity
of disability (taking account of any change in health status
over the individual’s lifetime). To quantify an individual’s
remaining life expectancy in terms of years lived in full
health, health-related quality of life weights are used to
weight survival in worse health states lower than survival
in full health. Table 1 also shows the expected number ofyears lived in full health and corresponding health-related
quality of life weights for the GOS outcomes [34].
The distribution of the overall health consequences of
uncertainty associated with the effectiveness of corticoste-
roids is illustrated in Fig. 3 for number of years lived in
full health per annum. On the balance of evidence about
total health outcomes (not just mortality), corticosteroids
were not expected to be effective (OR O 1.0). Therefore,
Fig. 3 describes the consequences of uncertainty surround-
ing the decision to not use corticosteroids in practice. It
shows that there was a 63% chance that this was the cor-
rect decision, that is, it did not result in a loss of years
lived in full health. However, there was a 37% chance that
corticosteroids could have improved health outcomes
(including a 23% chance of between 0 and 3,000 years
of full health gained per year and 14% chance of
O3,000 years of full health gained per year). The average
over the distribution in Fig. 3 of 1,067 years of full health
each year represents the health gains of resolving the
uncertainty through gathering additional evidence (e.g., a
large randomized trial to address the uncertainty in out-
comes after TBI).
At the time, 12% of patients with TBI received cortico-
steroids in the United Kingdom. Therefore, the value of
both implementing the uncertain findings of existing
research (not to use corticosteroids for TBI) and acquiring
additional evidence that would resolve this uncertainty was
greater at 1,264 years of full health gained each year.
Table 1. Proportion of individuals in each of the Glasgow Outcome Scale (GOS) health states based on a random-effects meta-analysis of the effect
of corticosteroids on survival and disability after traumatic brain injury
GOS outcome
Percentage of individuals (95% CI) by treatmenta Health-related quality of life
weight (SE)b Years lived in full healthcCorticosteroids No corticosteroids
Dead 33.5 (22.8, 45.2) 35.3 (24.8, 46.9) 0.00 0.00
Vegetative 4.8 (2.8, 7.5) 3.8 (2.4, 5.9) 0.08 (0.16) 0.56
Severe disability 13.5 (8.3, 20.1) 10.7 (7.1, 15.8) 0.26 (0.25) 3.24
Moderate disability 11.6 (8.6, 14.8) 12.1 (9.2, 15.1) 0.63 (0.27) 10.51
Good recovery 36.5 (28.1, 44.8) 38.0 (30.1, 45.6) 0.85 (0.19) 15.39
Abbreviations: CI, confidence interval; SE, standard error.
a Seven of the 16 trials reported outcomes in terms of the GOS [16,18e23], whereas a further two trials reported the combined effect on death,
vegetative, and severe disability [24,25].
b The conventional scale for health-related quality of life weights is between 0 (death) and 1 (perfect health). One year in a health state with a
weight of 0.5 is equivalent to half a year in full health. One study was identified which provided the health-related quality of life weights by GOS
outcomes [34].
c Quality-adjusted life expectancy quantifies an individual’s remaining life expectancy in terms of years lived in full health by weighing survival
in worse health states lower than survival in full health. One study was identified that estimated life expectancy in traumatic brain injury by age and
severity of disability and taking account of any change in health status over a person’s lifetime [35].
5C. McKenna et al. / Journal of Clinical Epidemiology - (2015) -5. Assessing the value and priority of proposed
research
Two questions are posed when considering whether the
decision to prioritize and commission CRASH was
appropriate:
1. Are the benefits of additional evidence of 1,264 years
of full health per year sufficient to regard CRASH as
potentially worthwhile?Fig. 3. Distribution of the consequences of uncertainty in number of years li
of the effect of corticosteroids on survival and disability after traumatic brain
tive at improving survival and disability. However, because of the uncertain
37% chance that a decision to not use corticosteroids is wrong. The numb
shown on the x-axis, whereas the y-axis shows the likelihood of these con
[1,1000] with a probability of 0.09 represents a 9% chance that the num
TBI is between 1 and 1,000 per annum.2. Should CRASH be prioritized over other research
topics that could be commissioned with the same
resources?
These assessments require a judgment of the period of
time over which the additional evidence is likely to be rele-
vant and the expected time it takes for the research to be
commissioned, conducted, and report. Information gener-
ated by research will not be valuable indefinitely because
of other changes occurring over time [3]. For example,ved in full health per annum based on a random-effects meta-analysis
injury (TBI). There is a 63% chance that corticosteroids are not effec-
ty in the effect of corticosteroids on survival and disability, there is a
er of lost years in full health as a consequence of this uncertainty is
sequences occurring. For example, the second bar corresponding to
ber of years of full health lost from not using corticosteroids after
Fig. 4. The value of additional evidence based on a random-effects meta-analysis of the effect of corticosteroids on survival and disability after
traumatic brain injury (TBI) before the definitive trial of CRASH was commissioned. The CRASH trial was proposed in the year 2000 but was
not expected to report before the year 2004. The value of resolving the uncertainty in the effect of corticosteroids on survival and disability
was 10,266 years of full health in the year 2000, with health benefits discounted at a rate of 3.5% per annum (or 13,904 years lived in full health
without discounting). CRASH, Corticosteroid Randomisation After Significant Head injury.
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able, making current comparators obsolete and rendering
information about their effectiveness irrelevant to future
clinical practice. The actual time horizon for evidence
generated by a particular research proposal is unknown
because it is a proxy for a complex and uncertain process
of future changes [36]. However, some judgment is un-
avoidable when making decisions about research priorities.
The CRASH trial was proposed to the UK Medical
Research Council (MRC) in the year 2000. A time horizon
of 15 years may have been a reasonable but conservative
judgment at the time, given that there were no other trials
underway and previously few major innovations which
had transformed the treatment or understanding of TBI.
The implications for an assessment of the overall expected
benefits of CRASH are illustrated in Fig. 4.
CRASH was not expected to report before the year 2004.
Therefore, the overall (undiscounted) expected health ben-
efits were an additional 13,904 years lived in full health
(1,264 years of full health per annum  11 years from
2004 to 2015). In the UK context, both health benefits
and National Health Service (NHS) costs are discounted
at a rate of 3.5%, so it is the discounted value of
10,266 years of full health that is most relevant. The ques-
tion remains, however, whether these expected benefits
were sufficient to justify the expected costs of the CRASH
trial (£2.2 million) and whether it represented a particular
priority compared with the other research that could have
been commissioned by the MRC using the same resources?
Oneway to address this question in theUnitedKingdom is
to ask whether the NHS could have generated similarexpected heath gains more effectively elsewhere or whether
the costs of the CRASH trial would have generated more
health benefits if these resources had been made available
to the NHS. Recent work in the United Kingdom [37] has
estimated the relationship between changes in NHS expendi-
ture and health outcomes. This work suggests that the NHS
spends approximately £75,000 to avoid one premature death,
£25,000 to gain one life year, and £20,000 to gain one quality-
adjusted life year [37]. Using these estimates, the costs of
CRASH could have been used to avoid 29 deaths
(5£2.2 m/£75,000) and generate 110 quality-adjusted life
years (5£2.2 m/£20,000) elsewhere in the NHSd
substantially less than the expected health benefits of the
CRASH trial. Alternatively, the NHS would have to spend
an additional £205 million (510,266 years of full
health  £20,000 for 1 year of full health) between 2004
and 2015 to generate expected health benefits similar to those
offered by CRASH. This strongly suggests that the CRASH
trial was indeed worthwhile at the time it was commissioned.
However, because the MRC itself has limited resources
and cannot draw directly on the NHS budget, it is possible
that other research proposed in the year 2000 may have been
even more valuable than CRASH. Without a similar reanal-
ysis of rejected research proposals at the time, it is not
possible to confirm that CRASH offered the greatest value.
If similar analysis was conducted for all topics competing
for limited research resources, it does become possible to
identify a shortlist of thosewhich are likely to beworthwhile.
It is useful to reconsider the analysis set out above once
the results of CRASH became available by updating
the meta-analysis and the estimates of the expected
7C. McKenna et al. / Journal of Clinical Epidemiology - (2015) -potential benefits of further research. When the results of
the CRASH trial are included in the meta-analysis, the
chance that corticosteroids improves mortality is reduced
to 0 (!0.0001), whereas the chance that corticosteroids
improves survival and quality of life is almost 0 (probability
of 0.005). Therefore, when the analysis of the potential
value of additional evidence is updated, there are no
expected benefits of acquiring additional evidence in TBI.
Therefore, CRASH was a definitive trial, appropriately
prioritized and commissioned at the time.6. Discussion
The above analysis has shown how methods of VOI
analysis can be integrated with the results of meta-
analysis to inform the assessments that are required when
making decisions about research priorities. The application
of VOI analysis to results from a standard meta-analysis is
not technically challenging nor does it pose any particular
computational problems. However, some of the contexts
to be examined may require more sophisticated forms of
meta-analysis (e.g., Bayesian meta-analysis to link multiple
end points) and careful consideration of the relevance and
quality of evidence (e.g., through the use of the Grading
of Recommendation, Assessment, Development, and Eval-
uation [GRADE] approach [38]). Nevertheless, it could be
argued that these methods would generally be required any-
way to estimate the effectiveness of the interventions even
before the value of additional evidence was considered.
In some circumstances, the end points included in the
meta-analysis of studies may not capture all valuable
aspects of health outcome; for example, mortality as a pri-
mary outcome after TBI was shown above to not neces-
sarily be the only relevant outcome. In these
circumstances, it may be possible to use external evidence
to link the end points to other aspects of health outcome, for
example, quality-adjusted life years. In other circum-
stances, it may be necessary to specify a minimum clinical
difference in outcomes (effect size) required to change clin-
ical practice as a means of incorporating concerns that there
are other important aspects of outcome (e.g., adverse events
or quality of life impacts that have not been accounted for
in the meta-analysis). Requiring that further research must
demonstrate larger differences in effect will tend to reduce
the expected benefits of research because larger differences
are less likely to be observed than smaller ones. Impor-
tantly, whatever the policy context, the principles and estab-
lished methods of VOI analysis are relevant to a wide range
of different types of health care systems and decision-
making contexts and should not be regarded as being
restricted to situations where probabilistic decision analytic
models or estimates of cost effectiveness are available.
Of course, no quantitative analysis can capture all
aspects of scientific and social value judgments about
research priorities. Therefore, the most relevant question
is whether these methods offer a practical and usefulstarting point for deliberation and add to the transparency
and accountability of research prioritization decisions.References
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